At the EAACI 2026 conference, dupilumab demonstrated superior outcomes over omalizumab in patients with severe asthma characterised by high biomarker levels. The development arrives at a critical juncture, drawing attention from both experts and the general public.
Medical experts say the results could inform future guidelines and practices in the healthcare field.
This is a developing situation, and further details are expected to emerge in the days ahead. The original source provides ongoing coverage.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medscape.com/